The Mounjaro weight loss jab: what you actually need to know

What does the Mounjaro jab actually do inside the body?

Tirzepatide, the active ingredient, binds to two receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both are gut hormones that your body already produces after eating. By amplifying their signals, Mounjaro slows how quickly food leaves the stomach, reduces appetite between meals, and helps regulate blood sugar. The practical result for most people is that they feel full sooner and stay full longer, not because of willpower, but because the biological signals that normally get overridden are being reinforced.

This dual action is what distinguishes it from semaglutide-based treatments, which target only the GLP-1 pathway. You can read more about how those mechanisms compare on our tirzepatide overview. The NHS's own information on the medicine explains the mechanism clearly if you'd like a second point of reference from a Tier-1 source: the NHS tirzepatide page covers what tirzepatide is, common side effects, and how it is taken.

Mounjaro has a Black Triangle (▼) label, which simply means the MHRA is still gathering real-world safety data. It doesn't mean the medicine is experimental (it has gone through full regulatory review) but it does mean that any side effects patients notice are especially worth reporting.

What kind of weight loss did people actually see in the trials?

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity (without diabetes) to tirzepatide or placebo over 72 weeks. At the 15 mg dose, participants lost an average of around 20-21% of body weight; some analyses put the figure closer to 22.5%. Those numbers are meaningful, but they come from a controlled trial setting with structured lifestyle support throughout, so they represent what is possible under ideal conditions, not a guarantee for any individual.

If you want to see a shorter-term picture, early results across the first eight weeks give a realistic sense of what the initial period looks like for most people. The SURMOUNT programme as a whole involved well over 10,000 participants across the SURPASS diabetes trials and SURMOUNT obesity trials combined, a large evidence base by any standard. NICE reviewed all of it when issuing its recommendation for tirzepatide (TA1026, published December 2024).

One thing worth saying plainly: the jab is not a shortcut. People who used it in trials were also following dietary guidance. The medicine makes sticking to that guidance considerably easier (the appetite suppression is real) but the lifestyle piece still matters for long-term outcomes.

Who is the Mounjaro weight loss jab licensed for?

Under UK licensing, tirzepatide is approved for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance, specifically a 2.5 kg/m² reduction for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds.

The licence covers private prescribing. The NHS has its own, stricter criteria under NICE TA1026, currently focused on people with BMI 35 or above plus multiple weight-related conditions, with the rollout expanding in phases. Many people who are clinically eligible don't yet qualify under the NHS phase they're in, or simply can't wait. Private prescribing through a regulated service is the alternative. Details of what the NHS route involves are on our Mounjaro weight loss page.

BMI alone never tells the whole story. A prescriber also considers your medical history, any medicines you take, and contraindications before issuing a prescription. Pregnancy, breastfeeding, and actively trying to conceive are situations where Mounjaro is not recommended. It is not licensed for under-18s. People with a history of medullary thyroid carcinoma or MEN2 should not take it.

What side effects should people starting the jab expect?

The most common ones are gastrointestinal: nausea, loose stools, constipation, indigestion, reflux, and burping. They tend to be at their worst in the first week or two after starting or after a dose increase, then ease off for most people as the body adjusts. Starting at 2.5 mg (rather than jumping straight to a higher dose) is specifically designed to reduce the chances of these being severe.

Fatigue, headache, dizziness, and mild injection-site reactions are also reported. Most people find these manageable and temporary. If you're considering whether this treatment is right for you, our guide to weight loss jabs with Mounjaro explains how the treatment works in practice and what to expect from the process. The situation to act on urgently is severe, persistent stomach pain that spreads toward the back, with or without vomiting, that pattern warrants medical attention promptly, as acute pancreatitis is a known (though uncommon) side effect of GLP-1 medicines. The MHRA highlighted this in a Drug Safety Update in January 2026. Patients can report any side effects through the Yellow Card scheme.

If you're weighing up side effects alongside cost and practicalities before making a decision, our Mounjaro pricing page covers what to expect from private treatment costs, and our FAQs address the questions our prescribers hear most often. When you're ready to talk it through properly, starting a free consultation is the way to get a prescriber's view on your individual situation, including a full explanation of how the Mounjaro jab is administered and what each step of treatment involves.